AR100095A1 - Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico - Google Patents

Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico

Info

Publication number
AR100095A1
AR100095A1 ARP150101148A ARP150101148A AR100095A1 AR 100095 A1 AR100095 A1 AR 100095A1 AR P150101148 A ARP150101148 A AR P150101148A AR P150101148 A ARP150101148 A AR P150101148A AR 100095 A1 AR100095 A1 AR 100095A1
Authority
AR
Argentina
Prior art keywords
fluoro
chloro
phenyl
solid forms
compound
Prior art date
Application number
ARP150101148A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR100095A1 publication Critical patent/AR100095A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente solicitud describe formas sólidas del compuesto de fórmula (1), los métodos para producirlos, así como composiciones que comprenden dichas formas sólidas. Reivindicación 1: Una forma sólida del compuesto de fórmula (1), seleccionado de e) una forma sustancialmente amorfa del compuesto de fórmula (1); f) un hemihidrato, hidrato, hemisolvato o solvato del compuesto de fórmula (1); o g) un polimorfo del compuesto de fórmula (1); o h) una sal farmacéuticamente aceptable del compuesto de fórmula (1).
ARP150101148A 2014-04-15 2015-04-15 Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico AR100095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461979649P 2014-04-15 2014-04-15

Publications (1)

Publication Number Publication Date
AR100095A1 true AR100095A1 (es) 2016-09-07

Family

ID=52815005

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101148A AR100095A1 (es) 2014-04-15 2015-04-15 Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico

Country Status (18)

Country Link
US (1) US10227298B2 (es)
EP (2) EP3459933B1 (es)
JP (2) JP6621761B2 (es)
KR (1) KR20160138307A (es)
CN (1) CN106458886A (es)
AR (1) AR100095A1 (es)
AU (1) AU2015249018A1 (es)
BR (1) BR112016023767A2 (es)
CA (1) CA2943571A1 (es)
ES (1) ES2928706T3 (es)
IL (1) IL247974A0 (es)
MA (1) MA39877A (es)
MX (1) MX2016013439A (es)
PL (1) PL3459933T3 (es)
RU (1) RU2016144187A (es)
SG (1) SG11201608559QA (es)
WO (1) WO2015158648A1 (es)
ZA (1) ZA201606653B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
WO2019213106A1 (en) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Solid state forms of idasanutlin
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
BR112014029530A2 (pt) * 2012-05-30 2017-06-27 Hoffmann La Roche compostos, composição farmacêutica e uso de um composto
MY192032A (en) * 2013-01-22 2022-07-24 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
EP2958893B1 (en) 2013-02-21 2017-05-03 F. Hoffmann-La Roche AG Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide

Also Published As

Publication number Publication date
EP3459933B1 (en) 2022-08-24
JP6887980B2 (ja) 2021-06-16
EP3459933A2 (en) 2019-03-27
SG11201608559QA (en) 2016-11-29
RU2016144187A3 (es) 2018-11-13
AU2015249018A1 (en) 2016-10-06
EP3459933A3 (en) 2019-05-29
BR112016023767A2 (pt) 2017-08-15
MA39877A (fr) 2017-02-22
CN106458886A (zh) 2017-02-22
JP6621761B2 (ja) 2019-12-18
IL247974A0 (en) 2016-11-30
JP2017511362A (ja) 2017-04-20
US20170037005A1 (en) 2017-02-09
JP2019055960A (ja) 2019-04-11
ZA201606653B (en) 2018-05-30
KR20160138307A (ko) 2016-12-02
RU2016144187A (ru) 2018-05-16
WO2015158648A1 (en) 2015-10-22
US10227298B2 (en) 2019-03-12
MX2016013439A (es) 2016-11-17
EP3131878A1 (en) 2017-02-22
ES2928706T3 (es) 2022-11-22
CA2943571A1 (en) 2015-10-22
PL3459933T3 (pl) 2023-01-23

Similar Documents

Publication Publication Date Title
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
PH12016500169A1 (en) Polymorph of syk inhibitors
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
WO2015195656A3 (en) Synthesis of polycyclic-carbamoylpyridone compounds
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
PH12016501517A1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
MX2020003020A (es) Compuestos de aminocarbonilcarbamato.
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
MX2020001157A (es) Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).
MX2015011375A (es) Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1].
EA201892235A1 (ru) Гранулированная композиция для перорального применения
AR100095A1 (es) Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
EA201691465A1 (ru) Средство для лечения сердечно-сосудистых заболеваний
MX2017012960A (es) Metodo para producir acilsulfamoilbenzamidas.
EA201690908A1 (ru) Пиразолопиримидиновые соединения
EA201791098A1 (ru) Способ синтеза производных бензазепина

Legal Events

Date Code Title Description
FB Suspension of granting procedure